Alnylam receives positive chmp opinion for vutrisiran for the treatment of attr amyloidosis with cardiomyopathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rna interference (rnai) therapeutics company, today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has adopted a positive opinion recommending approval of its rnai therapeutic vutrisiran for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (attr-cm). attr-cm is a debilitating, rapidly.
ALNY Ratings Summary
ALNY Quant Ranking